LENSAR receives certification for new adaptive cataract treatment system
The ALLY Adaptive Cataract Treatment System will be the first EU ALLY commercial installation
LENSAR is commercialising ALLY and expects to place the first systems with surgeons in the third quarter of 2024. Image credit: ©doganmesut – stock.adobe.com
LENSAR, Inc., a global medical technology company focused on advanced laser solutions for the treatment of cataracts, received certification for its ALLY Adaptive Cataract Treatment System under the European Union’s Medical Device Regulation (MDR).
The treatment is the first and only cataract laser to use artificial intelligence in the iris registration and surface identification of astigmatism management. It also can automatically determine cataract density, optimise fragmentation patterns and energy settings, and help contribute to quicker visual recovery and better patient outcomes, according to a press release from LENSAR.1
Having MDR certification will allow the company to start providing surgeons in the EU with a new transformative technology solution for cataract procedures. The ALLY is platform allows surgeons to perform a laser cataract procedure in a single, sterile environment. It also aims to improve both patient and practice efficiencies with enhanced speed and other features.
Nick Curtis, president and CEO of LENSAR, Inc., said, “We are thrilled to receive EU MDR certification for ALLY, which marks a significant milestone for LENSAR. We believe ALLY’s commercial availability in the EU creates a significant growth opportunity for us, through the ability to provide new capabilities and advanced next-generation laser technology to European surgeons.”
The ALLY System is also designed to address performance limitations associated with aging first-generation technologies. Physicians will be able to maximise efficiency in the operating room, as previous published time and motion studies for the treatment have shown. The studies saw significant procedure time was saved, resulting in increased revenue opportunities for both surgeons and ambulatory surgery centers. Results also showed less throughput time for patients.
“European cataract surgeons now have access to a technology that has demonstrated to not only enhance the precision, efficiency and patient satisfaction associated with the procedure, but also to significantly improve practice workflow and economics,” Curtis said.
LENSAR, Inc. is commercialising ALLY through its distributor network in the EU, expecting to place the first systems with surgeons in the third quarter of this year.
